Chief Scientist, Cellular Sciences
GE Healthcare Life Sciences, UK
Dr. Stephen Minger was appointed the Global Director for Research and Development for Cell Technologies at GE Healthcare in September 2009. Stephen received his PhD in Pathology (Neurosciences) in 1992 from the Albert Einstein College of Medicine in New York City. After post-doctoral work in central nervous system gene therapy, neural transplantation and neural stem cell biology at UCSD with Professor Fred “Rusty” Gage, he moved to the UK in 1996 and was appointed a Lecturer in Biomolecular Sciences at King's College London in 1998. He was appointed a Senior Lecturer in Stem Cell Biology in 2005 and was the Director of the Stem Cell Biology Laboratory from 2002 until joining GE Healthcare in 2009.
Over the past 20 years, Stephen’s research group has been at the forefront of human stem cell research. In 2002, together with Professor Peter Braude and Dr Susan Pickering, his research team was awarded one of the first two licenses granted by the UK Human Fertilisation and Embryology Authority for the derivation of human embryonic stem (hES) cells and his group was the first to deposit a human ES cell line into the UK Stem Cell Bank. Stephen was also one of the first two groups in the UK to be granted a research license by the HFEA in 2008 to pursue Somatic Cell Nuclear Transfer (SCNT) to generate “hybrid human embryos” for fundamental research into genetic forms of neurodegenerative conditions. He was actively involved with the UK Department of Health and with the Minister for Public Health in the consultation with both Houses of Parliament that led to the passage of the Human Embryo Bill of 2009 and the inclusion of new forms of animal-human embryos within primary legislation.
Stephen was the Stem Cell Expert and a Member of the UK Gene Therapy Advisory Committee (GTAC) at the Department of Health from 2006-2012 and was the Focal Point for Regenerative Medicine, Drug Discovery and Modernization of Traditional Chinese Medicine in China for the UK Department of Business, Innovation and Skills from 2006-2009. He has also been a an external consultant and reviewer to the European Commission Framework Programmes (FP6 and FP7) since 2003 to promote European-wide biomedical research, a member of the Grants Working Group of the California Institute of Regenerative Medicine since 2004, and is a member of the Scientific Advisory Committee of the Canadian Centre for the Commercialization of Regenerative Medicine.
In the summer of 2013, Stephen was appointed Chief Scientist for Cellular Sciences, GE Healthcare Life Sciences, and is now responsible for long-term global research strategy for technology development in cell therapy, regenerative medicine, cellular technologies, in vivo diagnostic imaging and molecular pathology/personalized medicine.Return to Board of Directors